Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in High-risk Localized Prostate Cancer
NCT01695473Phase 2Terminated
- Start
- Apr 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in prostate cancer (PCa). Primary endpoint: Percentage of Participants With Decrease in Phosphorylated S6 Immunohistochemistry (ICH) From Baseline up to 3 months. Started Apr 2013; status: terminated.
02
Drugs
buparlisib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01695473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01695473.